1.6K
Articles
47.8K
Citations
3.2
avg. Impact Factor
92
h-index

Most Cited Articles of Department of Oncology in 2015

TitleJournalYearCitations
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerNew England Journal of Medicine20151.4K
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6Lancet Oncology, The2015551
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncology, The2015428
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trialJournal of Clinical Oncology2015417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialLancet Oncology, The2015291
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancerAnnals of Oncology2015104
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal CarcinomatosisJournal of Thoracic Oncology201596
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment RegimensJournal of Thoracic Oncology201574
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patientsCancer Chemotherapy and Pharmacology201569
High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with SorafenibClinical Cancer Research201566
Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide studyClinical Infectious Diseases201562
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinomaAnnals of Oncology201558
Multi-subject atlas-based auto-segmentation reduces interobserver variation and improves dosimetric parameter consistency for organs at risk in nasopharyngeal carcinoma: A multi-institution clinical studyRadiotherapy and Oncology201552
Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapyClinical Cancer Research201551
IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancerOncotarget201549
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic ReviewCancer Research and Treatment201549
A Walk-and-Eat Intervention Improves Outcomes for Patients With Esophageal Cancer Undergoing Neoadjuvant ChemoradiotherapyOncologist201547
Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver CancerMolecular and Cellular Proteomics201546
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosisBMC Cancer201544
α-Enolase-binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancerScience Translational Medicine201541
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusionLung Cancer201541
MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studiesCancer Letters201541
NSCLC cells demonstrate differential mode of cell death in response to the combined treatment of radiation and a DNA-PKcs inhibitorOncotarget201540
Extranodal natural killer/T-cell lymphoma, nasal type in Taiwan: a relatively higher frequency of T-cell lineage and poor survival for extranasal tumorsHuman Pathology201540
Standardized uptake value and apparent diffusion coefficient of endometrial cancer evaluated with integrated whole-body PET/MR: Correlation with pathological prognostic factorsJournal of Magnetic Resonance Imaging201536